Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | QPCT | Q16769 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609136 | 0.91 | GAA (0.61) | GAAQPCTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31283170 | 0.83 | TLR2 (0.56) | GAAQPCTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13609286 | 0.83 | GAA (0.52) | USP2GAAQPCTMEN1KMT2A | |
| SCHEMBL18568234 | 0.80 | QPCT (0.65) | GAAQPCTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13416049 | 0.80 | QPCT (0.62) | QPCTMEN1KMT2ASMN1; SMN2NPC1 | |
| 2-Ethylhexanoic Acid SCHEMBL28899034 | 0.80 | TBXAS1 (0.67) | MAPK1 | |
| 2-Ethylhexanoic Acid SCHEMBL28899014 | 0.80 | TBXAS1 (0.67) | MAPK1 | |
| SCHEMBL11287686 | 0.79 | TBXAS1 (0.66) | — | |
| SCHEMBL11287681 | 0.79 | TBXAS1 (0.66) | — | |
| Hydrochloric Acid SCHEMBL11283441 | 0.78 | TBXAS1 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | claimed |
| EP-4346741-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | Solventum Intellectual Properties Company (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3883522-A1 | CURABLE COMPOSITION CONTAINING A POLYETHER-MODIFIED POLYDIMETHYL SILOXANE | 3M Innovative Properties Company (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2613754-B1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9216141-B2 | Curable composition, process of production and use thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2613754-A1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | 3M Innovative Properties Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130157226-A1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012033633-A1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| EP-2428199-A1 | Curable composition, process of production and use thereof | 3M Innovative Properties Company (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-0110429-B1 | RETARDERS FOR THE POLYMERISATION OF AZIRIDINE COMPOUNDS | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157226-A1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | LDHA, LDHB, SOD1 | USP2 2793/4885GAA 39/4885QPCT 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.